ABT logo

Abbott Laboratories (ABT) Accounts Receivable

Annual Accounts Receivable

$6.57 B
+$347.00 M+5.58%

31 December 2023

ABT Accounts Receivable Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Accounts Receivable

$7.05 B
+$197.00 M+2.87%

30 September 2024

ABT Quarterly Accounts Receivable Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ABT Accounts Receivable Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+5.6%+8.5%
3 y3 years+2.4%+10.1%
5 y5 years+26.7%+29.4%

ABT Accounts Receivable High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3 yearsat high+5.6%-2.1%+17.1%
5 y5 yearsat high+26.7%-2.1%+37.2%
alltimeall time-14.6%+427.6%-8.2%+466.6%

Abbott Laboratories Accounts Receivable History

DateAnnualQuarterly
Sept 2024
-
$7.05 B(+2.9%)
June 2024
-
$6.85 B(+3.8%)
Mar 2024
-
$6.61 B(+0.6%)
Dec 2023
$6.57 B(+5.6%)
$6.57 B(+1.0%)
Sept 2023
-
$6.50 B(+5.3%)
June 2023
-
$6.17 B(+2.5%)
Mar 2023
-
$6.02 B(-3.2%)
Dec 2022
$6.22 B(-4.1%)
$6.22 B(-3.0%)
Sept 2022
-
$6.41 B(-11.0%)
June 2022
-
$7.20 B(+0.3%)
Mar 2022
-
$7.18 B(+10.7%)
Dec 2021
$6.49 B(+1.1%)
$6.49 B(+1.3%)
Sept 2021
-
$6.41 B(+4.8%)
June 2021
-
$6.11 B(+0.3%)
Mar 2021
-
$6.10 B(-5.0%)
Dec 2020
$6.41 B(+18.2%)
$6.41 B(+13.5%)
Sept 2020
-
$5.65 B(+9.9%)
June 2020
-
$5.14 B(-2.9%)
Mar 2020
-
$5.29 B(-2.5%)
Dec 2019
$5.42 B(+4.7%)
$5.42 B(-0.5%)
Sept 2019
-
$5.45 B(-1.8%)
June 2019
-
$5.55 B(+3.8%)
Mar 2019
-
$5.34 B(+3.1%)
Dec 2018
$5.18 B(-1.3%)
$5.18 B(-1.7%)
Sept 2018
-
$5.27 B(+1.5%)
June 2018
-
$5.19 B(-3.1%)
Mar 2018
-
$5.36 B(+2.0%)
Dec 2017
$5.25 B(+61.6%)
$5.25 B(+9.4%)
Sept 2017
-
$4.80 B(+3.6%)
June 2017
-
$4.63 B(+2.7%)
Mar 2017
-
$4.51 B(+38.9%)
Dec 2016
$3.25 B(-5.0%)
$3.25 B(-2.2%)
Sept 2016
-
$3.32 B(-6.9%)
June 2016
-
$3.57 B(+4.0%)
Mar 2016
-
$3.43 B(+0.4%)
Dec 2015
$3.42 B(-4.7%)
$3.42 B(-1.2%)
Sept 2015
-
$3.46 B(-2.6%)
June 2015
-
$3.55 B(+2.1%)
Mar 2015
-
$3.48 B(-2.9%)
Dec 2014
$3.59 B(-10.0%)
$3.59 B(-0.9%)
Sept 2014
-
$3.62 B(-10.8%)
June 2014
-
$4.06 B(+4.5%)
Mar 2014
-
$3.88 B(-2.6%)
Dec 2013
$3.99 B(-47.6%)
$3.99 B(+2.7%)
Sept 2013
-
$3.88 B(-1.4%)
June 2013
-
$3.94 B(+0.5%)
Mar 2013
-
$3.92 B(-48.5%)
Dec 2012
$7.61 B(-0.9%)
$7.61 B(+9.6%)
Sept 2012
-
$6.95 B(+2.7%)
June 2012
-
$6.77 B(-11.6%)
Mar 2012
-
$7.66 B(-0.3%)
Dec 2011
$7.68 B(+7.0%)
$7.68 B(+9.1%)
Sept 2011
-
$7.04 B(+0.1%)
June 2011
-
$7.04 B(-1.7%)
Mar 2011
-
$7.16 B(-0.3%)
Dec 2010
$7.18 B(+9.8%)
$7.18 B(+15.0%)
Sept 2010
-
$6.25 B(-1.4%)
June 2010
-
$6.34 B(-2.8%)
Mar 2010
-
$6.52 B(-0.3%)
Dec 2009
$6.54 B
$6.54 B(+19.5%)
Sept 2009
-
$5.47 B(+0.4%)
June 2009
-
$5.45 B(+4.3%)
DateAnnualQuarterly
Mar 2009
-
$5.23 B(+4.7%)
Sept 2008
-
$4.99 B(-3.8%)
June 2008
-
$5.19 B(+3.8%)
Mar 2008
-
$5.00 B(+1.0%)
Dec 2007
$4.95 B(+16.9%)
$4.95 B(+17.5%)
Sept 2007
-
$4.21 B(+24.0%)
June 2007
-
$3.40 B(+3.6%)
Mar 2007
-
$3.28 B(-22.5%)
Dec 2006
$4.23 B(+18.3%)
$4.23 B(+18.3%)
Sept 2006
-
$3.58 B(-2.6%)
June 2006
-
$3.67 B(+9.9%)
Mar 2006
-
$3.34 B(-6.5%)
Dec 2005
$3.58 B(-3.2%)
$3.58 B(+11.7%)
Sept 2005
-
$3.20 B(-4.3%)
June 2005
-
$3.35 B(-5.4%)
Mar 2005
-
$3.54 B(-4.3%)
Dec 2004
$3.70 B(+11.6%)
$3.70 B(+25.5%)
Sept 2004
-
$2.95 B(+3.0%)
June 2004
-
$2.86 B(-10.6%)
Mar 2004
-
$3.20 B(-3.4%)
Dec 2003
$3.31 B(+13.2%)
$3.31 B(+15.0%)
Sept 2003
-
$2.88 B(+1.7%)
June 2003
-
$2.83 B(+2.6%)
Mar 2003
-
$2.76 B(-5.6%)
Dec 2002
$2.93 B(+4.1%)
$2.93 B(+2.2%)
Sept 2002
-
$2.87 B(+1.4%)
June 2002
-
$2.83 B(+6.9%)
Mar 2002
-
$2.64 B(-6.0%)
Dec 2001
$2.81 B(+29.1%)
$2.81 B(+4.6%)
Sept 2001
-
$2.69 B(+7.9%)
June 2001
-
$2.49 B(-2.5%)
Mar 2001
-
$2.55 B(+17.2%)
Dec 2000
$2.18 B(+6.0%)
$2.18 B(+7.4%)
Sept 2000
-
$2.03 B(-0.5%)
June 2000
-
$2.04 B(+5.1%)
Mar 2000
-
$1.94 B(-5.6%)
Dec 1999
$2.06 B(+5.1%)
$2.06 B(+9.2%)
Sept 1999
-
$1.88 B(-1.4%)
June 1999
-
$1.91 B(-3.7%)
Mar 1999
-
$1.98 B(+1.4%)
Dec 1998
$1.96 B(+9.7%)
$1.96 B(+12.9%)
Sept 1998
-
$1.73 B(-1.5%)
June 1998
-
$1.76 B(+3.4%)
Mar 1998
-
$1.70 B(-4.5%)
Dec 1997
$1.78 B(+4.3%)
$1.78 B(+4.8%)
Sept 1997
-
$1.70 B(-1.7%)
June 1997
-
$1.73 B(-0.1%)
Mar 1997
-
$1.73 B(+1.3%)
Dec 1996
$1.71 B(+9.3%)
$1.71 B(+10.3%)
Sept 1996
-
$1.55 B(-5.7%)
June 1996
-
$1.64 B(+5.2%)
Mar 1996
-
$1.56 B(-0.0%)
Dec 1995
$1.56 B(+6.4%)
$1.56 B(+6.3%)
Sept 1995
-
$1.47 B(-3.2%)
June 1995
-
$1.52 B(-1.9%)
Mar 1995
-
$1.55 B(+5.5%)
Dec 1994
$1.47 B(+9.9%)
$1.47 B(-0.2%)
Sept 1994
-
$1.47 B(+2.7%)
June 1994
-
$1.43 B(+6.2%)
Mar 1994
-
$1.35 B(+1.1%)
Dec 1993
$1.34 B(+7.4%)
$1.34 B(+7.4%)
Dec 1992
$1.24 B
$1.24 B

FAQ

  • What is Abbott Laboratories annual accounts receivable?
  • What is the all time high annual accounts receivable for Abbott Laboratories?
  • What is Abbott Laboratories annual accounts receivable year-on-year change?
  • What is Abbott Laboratories quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Abbott Laboratories?
  • What is Abbott Laboratories quarterly accounts receivable year-on-year change?

What is Abbott Laboratories annual accounts receivable?

The current annual accounts receivable of ABT is $6.57 B

What is the all time high annual accounts receivable for Abbott Laboratories?

Abbott Laboratories all-time high annual accounts receivable is $7.68 B

What is Abbott Laboratories annual accounts receivable year-on-year change?

Over the past year, ABT annual accounts receivable has changed by +$347.00 M (+5.58%)

What is Abbott Laboratories quarterly accounts receivable?

The current quarterly accounts receivable of ABT is $7.05 B

What is the all time high quarterly accounts receivable for Abbott Laboratories?

Abbott Laboratories all-time high quarterly accounts receivable is $7.68 B

What is Abbott Laboratories quarterly accounts receivable year-on-year change?

Over the past year, ABT quarterly accounts receivable has changed by +$552.00 M (+8.49%)